Revenue: As of FY2026 Q1, the actual value is USD 194.01 M, beating the estimate of USD 185.41 M.EPS: As of FY2026 Q1, the actual value is USD 0.EBIT: As of FY2026 Q1, the actual value is USD 22.38 M.<h4>Overall Financial Performance (Three Months Ended March 31)</h4><ul><li>Total revenue for GoodRx Holdings, Inc. decreased from $203.0 million in 2025 to $194.0 million in 2026.</li><li>Net income was $1.2 million in 2026, down from $11.1 million in 2025.</li><li>The net income margin decreased from 5.4% in 2025 to 0.6% in 2026.</li><li>Adjusted EBITDA decreased from $69.8 million in 2025 to $58.3 million in 2026, with the Adjusted EBITDA Margin decreasing from 34.4% to 30.0% over the same period.</li></ul><h4>Segment Revenue (Three Months Ended March 31)</h4><ul><li>Prescription transactions revenue decreased by - $35.2 million, or -24% year-over-year, from $148.9 million in 2025 to $113.7 million in 2026, primarily due to a decrease in Monthly Active Consumers and lower unit economics, partially offset by contributions from 2025 acquisitions.</li><li>Subscription revenue increased by $3.4 million, or 16% year-over-year, from $21.0 million in 2025 to $24.4 million in 2026, driven by the introduction of condition-specific subscription programs and an increase in subscription plans.</li><li>Pharma Direct revenue increased by $23.6 million, or 82% year-over-year, from $28.6 million in 2025 to $52.2 million in 2026, due to organic growth and expanded market penetration with pharma manufacturers.</li><li>Other revenue decreased by - $0.7 million, or -16% year-over-year, from $4.4 million in 2025 to $3.7 million in 2026.</li></ul><h4>Operational Costs (Three Months Ended March 31)</h4><ul><li>Cost of revenue increased by $6.8 million, or 51% year-over-year, from $13.4 million in 2025 to $20.2 million in 2026, primarily due to increased prescription delivery costs, fulfillment costs for Pharma Direct, and costs related to condition-specific subscription programs, with this cost expected to continue to grow year-on-year in the near term.</li><li>Product development and technology expenses remained relatively flat year-over-year at $30.2 million in 2026 compared to $31.1 million in 2025.</li><li>Sales and marketing expenses decreased by - $3.5 million, or -4% year-over-year, from $84.5 million in 2025 to $81.1 million in 2026, primarily due to a decrease in advertising expenses.</li><li>General and administrative expenses decreased by - $2.8 million, or -9% year-over-year, from $29.6 million in 2025 to $26.8 million in 2026, primarily due to a - $4.4 million impairment loss related to a leased office space in 2025.</li><li>Depreciation and amortization expenses remained relatively flat year-over-year at $21.8 million in 2026 compared to $20.9 million in 2025.</li><li>Interest income decreased by - $2.5 million, or -64% year-over-year, from $3.9 million in 2025 to $1.4 million in 2026, mainly due to lower average cash equivalent balances and interest rates.</li><li>Interest expense remained relatively flat year-over-year at - $9.8 million in 2026 compared to - $10.6 million in 2025.</li><li>Income tax expense decreased from - $5.6 million in 2025 to - $4.5 million in 2026, primarily due to a decrease in income before income taxes, partially offset by an increase in the estimated annual effective income tax rate and tax effects from equity awards.</li><li>The effective income tax rate increased from 33.7% in 2025 to 79.3% in 2026.</li></ul><h4>Cash Flow (Three Months Ended March 31)</h4><ul><li>Net cash provided by operating activities increased by $2.4 million year-over-year, from $9.4 million in 2025 to $11.8 million in 2026, driven by a - $14.1 million decrease in cash outflow from changes in operating assets and liabilities, partially offset by an - $11.6 million decrease in net income after non-cash adjustments.</li><li>Net cash used in investing activities decreased by $30.2 million year-over-year, from - $51.9 million in 2025 to - $21.6 million in 2026, almost entirely due to cash paid for a business acquisition in 2025.</li><li>Net cash used in financing activities decreased by $88.6 million year-over-year, from - $104.9 million in 2025 to - $16.3 million in 2026, almost entirely due to a decrease in payments for repurchases of Class A common stock.</li><li>Net change in cash and cash equivalents improved from - $147.4 million in 2025 to - $26.1 million in 2026.</li><li>Cash and cash equivalents at period end were $235.7 million as of March 31, 2026, compared to $301.0 million as of March 31, 2025.</li><li>An available revolving credit facility of $80.4 million was reported as of March 31, 2026.</li></ul><h4>Unique Metrics</h4><ul><li>Monthly Active Consumers decreased from 6.4 million as of March 31, 2025, to 5.3 million as of March 31, 2026, adversely impacted by changes in the retail pharmacy landscape and a reduction in an integrated savings program since Q2 2025.</li><li>Subscription Plans increased from 680 thousand as of March 31, 2025, to 717 thousand as of March 31, 2026.</li></ul><h4>Future Outlook and Strategy</h4>GoodRx Holdings, Inc. is focusing on expanding affordability and access through new initiatives like the Employer Direct platform and collaborations with pharmaceutical manufacturers, including participation in “TrumpRx.gov” which launched in February 2026 with initial demand in GLP-1 therapies. While external factors have negatively impacted prescription transactions revenue and Monthly Active Consumers, the company is strategically positioning its Pharma Direct and subscription offerings as key growth drivers. This transition is expected to have near-term impacts on prescription transactions unit economics and revenue in 2026 but is anticipated to enhance long-term growth and sustainable value.

GoodRx | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 194.01 M